Allogene Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 6, 2026

ALLO$0.93-12.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
Collaboration revenue - related party	$—	$—	$4,640	$—
Operating expenses:
Research and development	41,934	31,164	104,658	121,520
General and administrative	12,859	13,737	47,787	43,009
Impairment of long-lived assets	—	—	—	2,382
Total operating expenses	54,793	44,901	152,445	166,911
Loss from operations	(54,793)	(44,901)	(147,805)	(166,911)
Other income (expenses), net:
Interest and other income, net	4,879	3,926	13,099	15,629
Interest expense	(379)	(344)	(1,022)	(762)
Other income (expenses), net	(76)	(81)	75	(32)
Total other income (expenses), net	4,424	3,501	12,152	14,835
Net loss	(50,369)	(41,400)	(135,653)	(152,076)
Other comprehensive income (loss):
Net unrealized gain (loss) on available-for-sale investments	(925)	280	(1,712)	324
Net comprehensive loss	$(51,294)	$(41,120)	$(137,365)	$(151,752)
Net loss per share, basic and diluted	$(0.15)	$(0.19)	$(0.44)	$(0.70)
Weighted-average number of shares used in computing net loss per share, basic and diluted	346,092,814	222,038,680	305,492,175	218,800,085

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.